265 related articles for article (PubMed ID: 37944912)
1. Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
Fangusaro J; Jones DT; Packer RJ; Gutmann DH; Milde T; Witt O; Mueller S; Fisher MJ; Hansford JR; Tabori U; Hargrave D; Bandopadhayay P
Neuro Oncol; 2024 Jan; 26(1):25-37. PubMed ID: 37944912
[TBL] [Abstract][Full Text] [Related]
2. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
3. Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Mueller S; Fangusaro J; Thomas AO; Jacques TS; Bandopadhayay P; de Blank P; Packer RJ; Fouladi M; van Meeteren AS; Jones D; Perry A; Nakano Y; Hargrave D; Riedl D; Robison NJ; Partanen M; Fisher MJ; Witt O
Neuro Oncol; 2024 Mar; 26(3):407-416. PubMed ID: 38146999
[TBL] [Abstract][Full Text] [Related]
4. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
O'Hare P; Cooney T; de Blank P; Gutmann DH; Kieran M; Milde T; Fangusaro J; Fisher M; Avula S; Packer R; Fukuoka K; Mankad K; Mueller S; Waanders AJ; Opocher E; Bouffet E; Raabe E; Werle NE; Azizi AA; Robison NJ; Hernáiz Driever P; Russo M; Schouten N; van Tilburg CM; Sehested A; Grill J; Bandopadhayay P; Kilday JP; Witt O; Ashley DM; Ertl-Wagner BB; Tabori U; Hargrave DR
Neuro Oncol; 2024 May; ():. PubMed ID: 38743009
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics and therapeutic targets of pediatric low-grade gliomas.
Tateishi K; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2019 Apr; 36(2):74-83. PubMed ID: 30929113
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Pediatric Low-Grade Gliomas.
Sait SF; Giantini-Larsen AM; Tringale KR; Souweidane MM; Karajannis MA
Curr Neurol Neurosci Rep; 2023 Apr; 23(4):185-199. PubMed ID: 36881254
[TBL] [Abstract][Full Text] [Related]
8. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era.
Manoharan N; Liu KX; Mueller S; Haas-Kogan DA; Bandopadhayay P
Neoplasia; 2023 Feb; 36():100857. PubMed ID: 36566593
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and outcomes of pediatric intracranial gliomas: results from single center's 226 cases and corroborated with SEER database.
Chen Z; Guo Z; Wang J; Cao D; Xu Y; Dong F; Wan F
Childs Nerv Syst; 2023 Mar; 39(3):593-601. PubMed ID: 36662273
[TBL] [Abstract][Full Text] [Related]
10. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Sigaud R; Rösch L; Gatzweiler C; Benzel J; von Soosten L; Peterziel H; Selt F; Najafi S; Ayhan S; Gerloff XF; Hofmann N; Büdenbender I; Schmitt L; Foerster KI; Burhenne J; Haefeli WE; Korshunov A; Sahm F; van Tilburg CM; Jones DTW; Pfister SM; Knoerzer D; Kreider BL; Sauter M; Pajtler KW; Zuckermann M; Oehme I; Witt O; Milde T
Neuro Oncol; 2023 Mar; 25(3):566-579. PubMed ID: 35882450
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Dabrafenib in Pediatric Patients with
Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
[TBL] [Abstract][Full Text] [Related]
12. The Changing Landscape of Pediatric Low-Grade Gliomas: Clinical Challenges and Emerging Therapies.
Guerreiro Stucklin AS; Tabori U; Grotzer MA
Neuropediatrics; 2016 Apr; 47(2):70-83. PubMed ID: 26764564
[TBL] [Abstract][Full Text] [Related]
13. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
[TBL] [Abstract][Full Text] [Related]
14. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study.
Krishnatry R; Zhukova N; Guerreiro Stucklin AS; Pole JD; Mistry M; Fried I; Ramaswamy V; Bartels U; Huang A; Laperriere N; Dirks P; Nathan PC; Greenberg M; Malkin D; Hawkins C; Bandopadhayay P; Kieran MW; Manley PE; Bouffet E; Tabori U
Cancer; 2016 Apr; 122(8):1261-9. PubMed ID: 26970559
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
[TBL] [Abstract][Full Text] [Related]
16. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.
Ryall S; Zapotocky M; Fukuoka K; Nobre L; Guerreiro Stucklin A; Bennett J; Siddaway R; Li C; Pajovic S; Arnoldo A; Kowalski PE; Johnson M; Sheth J; Lassaletta A; Tatevossian RG; Orisme W; Qaddoumi I; Surrey LF; Li MM; Waanders AJ; Gilheeney S; Rosenblum M; Bale T; Tsang DS; Laperriere N; Kulkarni A; Ibrahim GM; Drake J; Dirks P; Taylor MD; Rutka JT; Laughlin S; Shroff M; Shago M; Hazrati LN; D'Arcy C; Ramaswamy V; Bartels U; Huang A; Bouffet E; Karajannis MA; Santi M; Ellison DW; Tabori U; Hawkins C
Cancer Cell; 2020 Apr; 37(4):569-583.e5. PubMed ID: 32289278
[TBL] [Abstract][Full Text] [Related]
17. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K
Nat Med; 2024 Jan; 30(1):207-217. PubMed ID: 37978284
[TBL] [Abstract][Full Text] [Related]
18. New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.
Raabe E; Kieran MW; Cohen KJ
Clin Cancer Res; 2013 Sep; 19(17):4553-8. PubMed ID: 23881924
[TBL] [Abstract][Full Text] [Related]
19. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
